Diamyd Medical (Germany) Investor Sentiment

DMN Stock  EUR 0.69  0.02  2.82%   
Roughly 62% of Diamyd Medical's investor base is looking to short. The analysis of current outlook of investing in Diamyd Medical AB suggests that many traders are alarmed regarding Diamyd Medical's prospects. The current market sentiment, together with Diamyd Medical's historical and current headlines, can help investors time the market. In addition, many technical investors use Diamyd Medical AB stock news signals to limit their universe of possible portfolio assets.
Diamyd Medical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Diamyd daily returns and investor perception about the current price of Diamyd Medical AB as well as its diversification or hedging effects on your existing portfolios.
  
over three months ago at news.google.com         
Major shareholder in Diamyd Medical announces subscription commitment in the rights issue - Marketsc...
Google News at Macroaxis
over three months ago at news.google.com         
Diamyd Medical receives SEK 48 million from exercise of warrants TO 3 - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical Clinical results with Diamyd Medicals study drug Remygen published in scientific jour...
Google News at Macroaxis
over six months ago at news.google.com         
Penser raises motivated value for Diamyd - increased probability of market approval - Marketscreener...
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical receives a second Fast Track designation from the FDA - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical AB Receives Second U.S. FDA Fast Track Designation for Diamyd - for the Prevention of...
Google News at Macroaxis
over six months ago at news.google.com         
8 biotech companies in Sweden you should know about - Labiotech.eu
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical publishes prospectus with regards to the rights issue - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, ...
Google News at Macroaxis
over six months ago at news.google.com         
The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 mi...
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical AB Reports Earnings Results for the Full Year Ended August 31, 2022 - Marketscreener....
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2015 - Marketscr...
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical AB Publ Reports Earnings Results for the Fourth Quarter Ended August 31, 2019 - Marke...
Google News at Macroaxis
over a year ago at news.google.com         
Companion Medical, Inc. announced that it has received 0.489999 million in funding from Diamyd Medic...
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA - Marketscreener.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Diamyd Medical that are available to investors today. That information is available publicly through Diamyd media outlets and privately through word of mouth or via Diamyd internal channels. However, regardless of the origin, that massive amount of Diamyd data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Diamyd Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Diamyd Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Diamyd Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Diamyd Medical alpha.

Diamyd Medical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Diamyd Stock analysis

When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets